These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22430426)

  • 1. [New model of the optimal oral antiplatelet treatment in patients with the ST-segment elevation myocardial infarction in Poland - authors' reply].
    Dudek D; Filipiak KJ; Stępińska J; Dziewierz A; Budaj A; Lesiak M; Witkowski A; Kuliczkowski W; Opolski G; Banasiak W
    Kardiol Pol; 2012; 70(3):317-20. PubMed ID: 22430426
    [No Abstract]   [Full Text] [Related]  

  • 2. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
    Koziński M; Grześk G; Kubica J
    Kardiol Pol; 2012; 70(2):206-12. PubMed ID: 22427098
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?
    Alexopoulos D; Moulias A; Kanakakis I; Xanthopoulou I
    Int J Cardiol; 2015 Sep; 194():41-3. PubMed ID: 26011263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the guidelines for the management of ST-elevation myocardial infarction.
    Levisman J; Price MJ
    Am J Cardiol; 2015 Mar; 115(5 Suppl):3A-9A. PubMed ID: 25728973
    [No Abstract]   [Full Text] [Related]  

  • 8. Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
    Cayla G; Collet JP; Silvain J; Montalescot G
    Arch Cardiovasc Dis; 2014 Jan; 107(1):1-3. PubMed ID: 24332911
    [No Abstract]   [Full Text] [Related]  

  • 9. Abciximab in the treatment of ST-segment elevation myocardial infarction.
    Tan DS; Sim DK; Chan ES; Tan RS
    JAMA; 2005 Oct; 294(14):1760-1; author reply 1761. PubMed ID: 16219877
    [No Abstract]   [Full Text] [Related]  

  • 10. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
    Grajek S
    Kardiol Pol; 2012; 70(2):213-4. PubMed ID: 22427099
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiplatelet agents in ischemic heart disease.
    May CH; Lincoff AM
    Handb Exp Pharmacol; 2012; (210):495-518. PubMed ID: 22918744
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes.
    Puma JA; Sketch MH
    J Am Osteopath Assoc; 2000 Nov; 100(11 Suppl):S8-12. PubMed ID: 11191119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological facilitation of coronary intervention in ST-segment elevation myocardial infarction: time is of the essence.
    Gersh BJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1292-4. PubMed ID: 21232724
    [No Abstract]   [Full Text] [Related]  

  • 16. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 17. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual antiplatelet therapy duration and mortality - Authors' reply.
    Yeh RW; Elmariah S; Doros G; Kereiakes DJ; Mauri L
    Lancet; 2015 May; 385(9983):2149-50. PubMed ID: 26068262
    [No Abstract]   [Full Text] [Related]  

  • 19. Influences of hemodilution and anticoagulation on antiplatelet P2Y12 therapy: in vitro whole blood perfusion model.
    Ogawa S; Hosokawa K; Tanaka KA
    J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):e69-71. PubMed ID: 24090800
    [No Abstract]   [Full Text] [Related]  

  • 20. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.